At a glance
ClinicalIndex Comparison RecordN/ACompleted· 19,467 enrolled
Drug / intervention
Tiotropium+Olodaterol +3 moredrug
Likely dose
Tiotropium+Olodaterol via Spiolto Respimat inhaler (specific dose not stated)AI-extracted
Key inclusion· 4
- ✓At least one prescription for Tiotropium+Olodaterol (fixed dose or free combination) as new initiation between January 1, 2014 and December 31, 2019
- ✓Age ≥40 years on index date
- ✓At least one diagnosis of COPD at any time prior to or on the index date
- ✓At least one year of continuous medical and health insurance plan prior to index date
Key exclusion· 2
- ✕Any use of Tiotropium+Olodaterol in free or fixed form within one year prior to the index date
- ✕History of asthma, allergic rhinitis, lung cancer, interstitial lung disease, or lung transplant
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety Profile of Tiotropium + Olodaterol Used as Maintenance Treatment in COPD Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
In Brief
An observational study evaluating Tiotropium+Olodaterol, Spiolto Respimat, and 2 other interventions for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 19,467 participants across 1 site.
Detailed Summary
The aim of this real world study is to assess the safety profile of tiotropium/olodaterol (Tio/Olo).
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesChina
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
First PostedMay 2022
Enrollment StartSep 2022
Primary CompletionDec 2022
TodayJul 2026
First PostedMay 26, 2022
Enrollment StartSep 30, 2022
Primary CompletionDec 7, 2022
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 4.1 years ago
Interventions
Tiotropium+Olodateroldrug
Tiotropium+Olodaterol
Spiolto Respimatdevice
Spiolto Respimat Inhaler device
Long-acting muscarinic antagonists (LAMAs)drug
Long-acting muscarinic antagonists (LAMAs)
Long-acting β2-agonists (LABAs)drug
Long-acting β2-agonists (LABAs)